NCT06354140View on ClinicalTrials.gov

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2028

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Tegafur

Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year. Tegafur: body surface area (BSA) \< 1.25m2, use 80mg; 1.25-1.5m2, use 100mg; \> 1.5m2, use 120mg. Treatment for 1 year

Trial Locations (1)

400042

RECRUITING

Army Medical Center of the People's Liberation Army, Chongqing

All Listed Sponsors
lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER